Mianserin hydrochloride
Mianserin is a tetracyclic antidepressant used in the treatment of depressive illness.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It enhances central noradrenergic transmission largely through antagonism of presynaptic alpha-2 adrenoceptors, and also blocks several serotonin and histamine receptors.
Prescribing in practice
- Mianserin can cause bone marrow suppression including agranulocytosis, so any signs of infection such as fever, sore throat or stomatitis should prompt an urgent full blood count and review.
- It is sedating, which may be useful where insomnia accompanies depression but increases the risk of drowsiness and falls, particularly in older people.
- As with all antidepressants, monitor for suicidal thoughts and behaviour, especially early in treatment and in younger adults.
Monitoring
A full blood count should be checked if signs of infection develop, and patients should be monitored for mood changes and emergent suicidal ideation during treatment.
Counselling the patient
- Report any fever, sore throat, mouth ulcers or other signs of infection without delay.
- This medicine can make you drowsy, so take care with driving and alcohol.
- Do not stop the medicine abruptly; your prescriber will advise on tapering.
Evidence & guidelines
Mianserin is an established antidepressant, and the requirement to investigate signs of infection because of the risk of blood dyscrasias is reflected in its product information.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185